Adenobio is a privately owned emerging company founded in 2003 to develop a new generation of parenteral adenosine-enhanced medicines based on a totally new concept. The company is incorporated in the Netherlands and operates from Amsterdam. Most of the R & D takes place in Europe with a particular preference for France.

The company has now two injectable candidate products in human clinical trials targeting four areas, cardiac imaging (pharmacological agent), cardioprotection during  coronary revascularization procedures, stimulation of angiogenesis after myocardial infarction  and acute ischemic stroke. One oral product is also currently being developed for sexual dysfunction.

• Adenosoft is a myocardial perfusion imaging product which has completed Phase II b. It is given as a single unit dosage form during a 4 minute intravenous infusion. Injection of the tracer is done after 2.5 minutes. The dose is weight adjusted. The product has a short duration of action. It is equivalent in terms of efficacy to the reference drug Adenoscan but also exhibits very significant reductions in the occurrence and severity of A1 side effects (e.g chest pain) and A2 side effects ( e.g flushing, dyspnea). Actually this product has a better profile than all existing competitors including new adenosine A2a agonists. Due to Adenosoft 's characteristics there is the possibility of Phase III with a limited number of patients and for targeting an NDA within 3 years.
• BIdosine LI: has demonstrated cardioprotective and neurorepairing effects in animal studies. Bidosine LI has a potential for at least 3 different indications: it is  intended for use as an adjunct to reperfusion procedures during acute coronary syndromes - it is also intended for use early after myocardial infarction for patients  with significantly reduced ejection fraction to stimulate angiogenesis and improve cardiac function . Among other potential applications Bidosine LI can also position itself as a drug-candidate for acute ischemic stroke. Currently starting  Phase I.
• PUR-201: for mild to moderate sexual dysfunction. This product was designed for the nutraceutical market.

INNOVATIVE ASPECTS:

Adenobio’s efforts have been focused in finalizing:

1. Compounds with improved adenosine efficacy/safety ratio, i.e with unchanged efficacy, unchanged reactivity compared to adenosine but with improved safety and increased comfort for patients. Side  effects appear  to be further reduced with Adenobio's compounds as compared to  selective adenosine agonists.
2. Compounds with superior cell protective and repairing activities than adenosine itself.
3. Compounds based on a new concept :"the modulation of adenosine plasma clearance".

MAIN ADVANTAGES:  The duration of action of Adenobio’s parenteral products is short and very comparable to that of adenosine, which is a clear advantage with respect to side effects. The active ingredients of Adenobio‘s product are known molecules, which should accelerate the development program and time to approval whilst also greatly reduce the risk of failure before registration. Adenobio’s products have the potential to be extremely cost-competitive if necessary with low cost of goods that can secure profit margins.

Patents have been applied for Adenosoft and Bidosine, both for composition and method of use. Potential patent’s life / priority date = 19 years.

The patent protecting PUR-201 has already been issued in the US and in Europe. Issue in Japan is pending.

Adenobio will study all type of proposal.